Completed

Antidiabetic Medications and Risk of Cancer

Lead sponsor

University of Pecs

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Actual enrollment

74,799

Study population

Type 2 diabetes

Eligibility highlights

Primary endpoint

•Overall cancer risk

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07628556

Org study IDPTE Antidiab_cc_2026

Timeline

Milestones

Study start2025-03-15actual

Primary completion2025-12-30actual

Study completion2025-12-30actual

Study first posted2026-06-05actual

Last update posted2026-06-05actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age19 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

The source population consisted of all individuals aged ≥19 years on 1 January 2016 who had no inpatient or outpatient care for malignant disease between 2009 and 2015 and no antidiabetic drug dispensing between 2011-2015. The primary study population included individuals from this source population who dispensed any antidiabetic medication between 2016 and 2022.

Inclusion criteria

•Type 2 diabetes mellitus

•Antidiabetic medication initiators

Exclusion criteria

•Antidiabetic prescription in the previous 5 years

•Recent pancreatectomy (previous or subsequent 90 days after inclusion)

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

12 endpoints

Primary/protocol endpoint/low confidence

Overall cancer risk

Time frame:2016-2022

descriptive